Bayer HOT Aspirin Study Interpretation Gets Lukewarm FDA Feedback
This article was originally published in The Tan Sheet
Executive Summary
FDA's review of the studies used by Bayer to support an aspirin indication for primary prevention of myocardial infarction suggests "a substantially weaker result than is published," according to the agency